Larionova Irina, Rakina Militsa, Ivanyuk Elena, Trushchuk Yulia, Chernyshova Alena, Denisov Evgeny
Laboratory of Cancer Progression Biology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 634009, Tomsk, Russia.
Laboratory of Translational Cellular and Molecular Biomedicine, National Research Tomsk State University, Tomsk, 634050, Tomsk, Russia.
J Cancer Res Clin Oncol. 2022 May;148(5):1015-1031. doi: 10.1007/s00432-022-03923-4. Epub 2022 Feb 3.
Radiotherapy (RT) is considered as a standard in the treatment of most solid cancers, including glioblastoma, lung, breast, rectal, prostate, colorectal, cervical, esophageal, and head and neck cancers. The main challenge in RT is tumor cell radioresistance associated with a high risk of locoregional relapse and distant metastasis. Despite significant progress in understanding mechanisms of radioresistance, its prediction and overcoming remain unresolved. This review presents the state-of-the-art for the potential universal biomarkers correlated to the radioresistance and poor outcome in different cancers. We describe radioresistance biomarkers functionally attributed to DNA repair, signal transduction, hypoxia, and angiogenesis. We also focus on high throughput genetic and proteomic studies, which revealed a set of molecular biomarkers related to radioresistance. In conclusion, we discuss biomarkers which are overlapped in most several cancers.
放射疗法(RT)被视为大多数实体癌治疗的标准方法,包括胶质母细胞瘤、肺癌、乳腺癌、直肠癌、前列腺癌、结直肠癌、宫颈癌、食管癌以及头颈癌。放射疗法的主要挑战在于肿瘤细胞的放射抗性,这与局部区域复发和远处转移的高风险相关。尽管在理解放射抗性机制方面取得了显著进展,但其预测和克服方法仍未得到解决。本综述介绍了与不同癌症中的放射抗性和不良预后相关的潜在通用生物标志物的最新研究状况。我们描述了在功能上归因于DNA修复、信号转导、缺氧和血管生成的放射抗性生物标志物。我们还关注高通量基因和蛋白质组学研究,这些研究揭示了一组与放射抗性相关的分子生物标志物。总之,我们讨论了在大多数几种癌症中重叠的生物标志物。